SMARCA4 and neoplasm: Acase report on the long-lasting response of Pembrolizumab showed that a 58-year-old woman diagnosed with a SMARCA4-deficient malignant rhabdoid tumor-like tumor, characterized by dual loss of SMARCA4 and SMARCA2 on IHC had remarkable symptomatic recovery from the treatment.